Company Overview of Trinseo S.A.
Trinseo S.A., a materials company, manufactures and markets synthetic rubber, latex binders, and plastic products in Europe, North America, Latin America, and the Asia Pacific. The company operates through Latex Binders, Synthetic Rubber, Performance Plastics, Basic Plastics, Feedstocks, and Americas Styrenics segments. The Latex Binders segment offers styrene-butadiene, styrene-acrylate, vinylidene chloride, and butadiene-methacrylate latex products for the commercial and niche carpet markets, as well as performance latex products for the adhesive, building and construction, and technical textile paper markets. The Synthetic Rubber segment provides styrene-butadiene rubber, lithium polybuta...
1000 Chesterbrook Boulevard
Berwyn, PA 19312
Founded in 2010
Key Executives for Trinseo S.A.
Chief Executive Officer, President and Director
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $259.6K
Senior Vice President and Business President of Basic Plastics & Feedstocks
Total Annual Compensation: $914.1K
Senior Vice President and Business President of Performance Materials
Total Annual Compensation: $656.5K
Chief Legal Officer, Senior Vice President and Corporate Secretary
Total Annual Compensation: $430.0K
Compensation as of Fiscal Year 2016.
Trinseo S.A. Key Developments
Trinseo Offers Medical Grade MAGNUM™ ABS for Medical Equipment
Apr 10 17
Trinseo announced that it is offering medical equipment manufacturers and molders medical-grade MAGNUM™ ABS Resins. The material features the advantages of Trinseo’s mass polymerization technology combined with the properties needed most for medical applications to assure the integrity of end-use applications. Trinseo’s MAGNUM™ 8391 MED ABS Resins, are part of the company’s line of performance plastics tailored for medical device applications. Trinseo’s proprietary polymerization process results in a material that is highly consistent from lot-to-lot in terms of color, rheology and physical properties. The process results in brilliant whiteness of the material for ease of coloring and less pigment use, and results in lower residual monomers and oligomers. Medical-industry requirements found in MAGNUM™ 8391 MED include biocompatibility, chemical resistance, sterilization options, and comprehensive regulatory support. The material also offers an extended notification of change as well as the versatility of secondary operations common in medical equipment, such as spraying, plating, solvent bonding and ultrasonic welding. To ensure the quality required for medical applications, Trinseo adheres to strict production guidelines. Medical manufacturing facilities and related global departments are ISO 13485:2016 certified, which places a special emphasis on risk management and process validation.
Trinseo S.A. Presents at Barclays Materials ROC Stars Conference, Mar-28-2017
Mar 10 17
Trinseo S.A. Presents at Barclays Materials ROC Stars Conference, Mar-28-2017 . Venue: Barclays - New York, 745 Seventh Avenue, 32nd Floor, New York, NY 10019, United States.
Trinseo S.A. Presents at Deutsche Bank Basic Materials One-on-One Day, Mar-14-2017
Mar 9 17
Trinseo S.A. Presents at Deutsche Bank Basic Materials One-on-One Day, Mar-14-2017 . Venue: Boston Harbor Hotel, 70 Rowes Wharf, Boston, MA 02210, United States. Speakers: Andrew Myers, Director, IR and Corporate Treasury, Christopher Daniel Pappas, Chief Executive Officer, President and Director, David P. Stasse, Vice President of Treasury & Corporate Finance and Treasurer.
Similar Private Companies By Industry
Recent Private Companies Transactions